Jacobs & CO Abb Vie Inc. Transaction History

Jacobs & CO

$1 Billion
Q3 2024

A detailed history of Jacobs & CO transactions in Abb Vie Inc. stock. As of the latest transaction made, Jacobs & CO holds 60,926 shares of ABBV stock, worth $10.8 Million. This represents 1.2% of its overall portfolio holdings.

Number of Shares

60,926

Previous 61,845 1.49%

Holding current value

$10.8 Million

Previous $10.6 Million 13.43%

% of portfolio

1.2%

Previous 1.11%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 01, 2024	SELL	$163.84 - $199.33 $150,568 - $183,184	-919 Reduced 1.49%	60,926 $12 Million
Q2 2024 Jul 12, 2024	BUY	$154.79 - $180.76 $100,458 - $117,313	649 Added 1.06%	61,845 $10.6 Million
Q1 2024 Apr 12, 2024	SELL	$159.82 - $182.1 $277,607 - $316,307	-1,737 Reduced 2.76%	61,196 $11.1 Million
Q4 2023 Jan 17, 2024	SELL	$137.6 - $154.97 $40,179 - $45,251	-292 Reduced 0.46%	62,933 $9.75 Million
Q3 2023 Oct 13, 2023	SELL	$133.59 - $154.65 $128,647 - $148,927	-963 Reduced 1.5%	63,225 $9.42 Million
Q2 2023 Jul 11, 2023	SELL	$132.51 - $164.9 $1.03 Million - $1.28 Million	-7,772 Reduced 10.8%	64,188 $8.65 Million
Q1 2023 Apr 17, 2023	SELL	$144.61 - $166.54 $349,522 - $402,527	-2,417 Reduced 3.25%	71,960 $11.5 Million
Q4 2022 Jan 13, 2023	BUY	$138.31 - $165.87 $132,224 - $158,571	956 Added 1.3%	74,377 $12 Million
Q3 2022 Oct 11, 2022	SELL	$134.21 - $153.93 $118,104 - $135,458	-880 Reduced 1.18%	73,421 $9.85 Million
Q2 2022 Jul 19, 2022	SELL	$137.62 - $174.96 $242,348 - $308,104	-1,761 Reduced 2.32%	74,301 $11.4 Million
Q1 2022 Apr 14, 2022	SELL	$131.98 - $163.75 $201,533 - $250,046	-1,527 Reduced 1.97%	76,062 $12.3 Million
Q4 2021 Jan 21, 2022	BUY	$107.43 - $135.93 $277,921 - $351,650	2,587 Added 3.45%	77,589 $10.5 Million
Q3 2021 Oct 13, 2021	BUY	$106.4 - $120.78 $480,183 - $545,080	4,513 Added 6.4%	75,002 $8.09 Million
Q2 2021 Jul 15, 2021	SELL	$105.21 - $117.21 $208,315 - $232,075	-1,980 Reduced 2.73%	70,489 $7.94 Million
Q1 2021 Apr 05, 2021	SELL	$102.3 - $112.62 $57,288 - $63,067	-560 Reduced 0.77%	72,469 $7.84 Million
Q4 2020 Jan 12, 2021	BUY	$80.49 - $108.67 $77,109 - $104,105	958 Added 1.33%	73,029 $7.83 Million
Q3 2020 Dec 03, 2020	BUY	$85.91 - $100.83 $619,325 - $726,883	7,209 Added 11.11%	72,071 $6.31 Million
Q2 2020 Jul 09, 2020	BUY	$73.37 - $98.18 $293,480 - $392,720	4,000 Added 6.57%	64,862 $6.37 Million
Q1 2020 Apr 13, 2020	BUY	$64.5 - $97.79 $259,290 - $393,115	4,020 Added 7.07%	60,862 $4.64 Million
Q4 2019 Jan 29, 2020	BUY	$72.13 - $90.25 $154,141 - $192,864	2,137 Added 3.91%	56,842 $5.03 Million
Q3 2019 Nov 04, 2019	SELL	$62.98 - $75.72 $179,744 - $216,104	-2,854 Reduced 4.96%	54,705 $4.14 Million
Q2 2019 Aug 01, 2019	SELL	$65.7 - $83.98 $165,301 - $211,293	-2,516 Reduced 4.19%	57,559 $4.19 Million
Q1 2019 Apr 29, 2019	SELL	$77.14 - $90.79 $202,261 - $238,051	-2,622 Reduced 4.18%	60,075 $4.84 Million
Q4 2018 Feb 07, 2019	SELL	$77.85 - $96.01 $705,009 - $869,466	-9,056 Reduced 12.62%	62,697 $5.78 Million
Q3 2018 Oct 23, 2018	BUY	$88.91 - $98.84 $194,535 - $216,261	2,188 Added 3.15%	71,753 $6.79 Million
Q2 2018 Jul 19, 2018	SELL	$89.78 - $106.23 $89,331 - $105,698	-995 Reduced 1.41%	69,565 $6.45 Million
Q1 2018 Apr 30, 2018	SELL	$92.01 - $123.21 $204,722 - $274,142	-2,225 Reduced 3.06%	70,560 $6.68 Million
Q4 2017 Feb 09, 2018	SELL	$89.56 - $98.21 $267,784 - $293,647	-2,990 Reduced 3.95%	72,785 $7.04 Million
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $5.29 Million - $6.76 Million	75,775	75,775 $6.73 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $315B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs & CO with notifications on news.

Account